PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Parkinson's disease (Ropinirole hydrochloride - Parkinson's disease)

Records returned : 27 (on 21 Nov 2024 at 12:32:23). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
04.09.01
Ropinirole hydrochloride
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Pramipexole
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Entacapone
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
Preferred
Preferred COMT inhibitor
04.09.01
Rotigotine
Parkinson's disease
Blue
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
Consider patches if levodopa and / or oral dopamine are not effective in treating nocturnal akinesia
04.09.01
Amantadine hydrochloride
Parkinson's disease
Blue
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Selegiline hydrochloride
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Levodopa with carbidopa and entacapone
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.09.01
Rasagiline mesilate
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
04.08.02
Clonazepam
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Rapid eye movement disorder
04.01.01
Melatonin
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Rapid eye movement disorder.
Generic 2mg MR tablets.
04.09.01
Co-beneldopa
Parkinson's disease
Blue
Formulations :
  • Capsules
  • Capsules (slow release)
  • Dispersible tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Co-careldopa
Parkinson's disease
Blue
Formulations :
  • Tablets
  • Tablets (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Opicapone
Parkinson's disease
Blue
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
2nd line COMT inhibitor. Entacapone is the locally agreed 1st-line choice
04.09.01
Tolcapone
Parkinson's disease
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.09.01
Apomorphine hydrochloride
Parkinson's disease
Amber
Formulations :
  • Pre-filled syringe
  • Subcutaneous injection (sc)
  • Subcutaneous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
06.07.01
Bromocriptine
Parkinson's disease
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.09.01
06.07.01
Cabergoline
Parkinson's disease
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.09.01
Pergolide mesilate
Parkinson's disease
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.09.01
Co-careldopa
Parkinson's disease
Red
Formulations :
  • Intestinal gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Foslevodopa with foscarbidopa
Parkinson's disease
N/A
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
04.09.01
Levodopa with carbidopa and entacapone
Parkinson's disease
N/A
Formulations :
  • Intestinal gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD2
NHSE
04.09.02
Orphenadrine hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
04.09.02
Procyclidine hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
04.09.02
Trihexyphenidyl hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
04.09.01
Safinamide
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More